Abstract:Adenosine is an evolutionary ancient metabolic regulator linking energy state to physiologic processes, including immunomodulation and cell proliferation. Tumors create an adenosine-rich immunosuppressive microenvironment through the increased release of ATP from dying and stressed cells and its ectoenzymatic conversion into adenosine. Therefore, the adenosine pathway becomes an important therapeutic target to improve the effectiveness of immune therapies. Prior research has focused largely on the two major ectonucleotidases, ectonucleoside triphosphate diphosphohydrolase 1/cluster of differentiation (CD)39 and ecto-5'-nucleotidase/CD73, which catalyze the breakdown of extracellular ATP into adenosine, and on the subsequent activation of different subtypes of adenosine receptors with mixed findings of antitumor and protumor effects. New findings, needed for more effective therapeutic approaches, require consideration of redundant pathways controlling intratumoral adenosine levels, including the alternative NAD-inactivating pathway through the CD38-ectonucleotide pyrophosphatase phosphodiesterase (ENPP)1-CD73 axis, the counteracting ATP-regenerating ectoenzymatic pathway, and cellular adenosine uptake and its phosphorylation by adenosine kinase. This review provides a holistic view of extracellular and intracellular adenosine metabolism as an integrated complex network and summarizes recent data on the underlying mechanisms through which adenosine and its precursors ATP and ADP control cancer immunosurveillance, tumor angiogenesis, lymphangiogenesis, cancer-associated thrombosis, blood flow, and tumor perfusion. Special attention is given to differences and commonalities in the purinome of different cancers, heterogeneity of the tumor microenvironment, subcellular compartmentalization of the adenosine system, and novel roles of purine-converting enzymes as targets for cancer therapy. Significance Statement The discovery of the role of adenosine as immune checkpoint regulator in cancer has led to the development of novel therapeutic strategies targeting extracellular adenosine metabolism and signaling in multiple clinical trials and preclinical models. Here we identify major gaps in knowledge that need to be filled to improve the therapeutic gain from agents targeting key components of the adenosine metabolic network and, on this basis, provide a holistic view of the cancer purinome as a complex and integrated network.

The role of the CD39–CD73–adenosine pathway in liver disease

Detrimental Effects of Adenosine Signaling in Sickle Cell Disease

Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities

CD39/CD73/A2AR pathway and cancer immunotherapy

CD73, a Significant Protein in Liver Diseases.

Beneficial and Detrimental Role of Adenosine Signaling in Diseases and Therapy.

Biological roles of CD39 in translational medicine

Adenosine-mediated immune responses in inflammatory bowel disease

The Ectonucleotidases CD39 and CD73 on T Cells: the New Pillar of Hematological Malignancy

Ectonucleotidases in Ischemia Reperfusion Injury: Unravelling the Interplay With Mitochondrial Dysfunction in Liver Transplantation

Adenosinergic metabolism pathway: an emerging target for improving outcomes of solid organ transplantation

The different effects of four adenosine receptors in liver fibrosis

CD39 Transforming Cancer Therapy by Modulating Tumor Microenvironment

Disordered Purinergic Signaling and Abnormal Cellular Metabolism Are Associated with Development of Liver Cancer in Cd39/ENTPD1 Null Mice.

Purinergic signaling in liver disease: calcium signaling and induction of inflammation

Purinergic signalling in the liver in health and disease

Purinergic Signaling in Non-Parenchymal Liver Cells

CD73: Friend or Foe in Lung Injury

The Immune Regulatory Role of Adenosine in the Tumor Microenvironment

Abstract 12514: Elevated Intracellular Adenosine Epigenetically Regulates Endothelial Inflammation <i>(Best of Basic Science Abstract)</i>

ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain